ライフサイエンスコーパス: mutational burden

1 iduals with BBS, irrespective of their known mutational burden.

2 ten resulting in GBM characterized by a high mutational burden.

3 t TP53 gain-of-function mutations and a high mutational burden.

4 sequencing data of large cohorts with a high mutational burden.

5 oms, which show gender-specific liability to mutational burden.

6 complished without a substantial increase in mutational burden.

7 tionary history, and organisms' tolerance of mutational burden.

8 tivity correlated negatively with increasing mutational burden.

9 er types and amplified tumors have increased mutational burden.

10 stability (7.6% [13 of 170]), and high tumor mutational burden (9.5% [30 of 317]) were all enriched i

11 position of the mutation in the protein, the mutational burden among healthy individuals and membersh

12 esence of POLE mutation associates with high mutational burden and elevated expression of several imm

13 gree of tumor "foreignness," as reflected by mutational burden and expression of viral genes, (2) the

14 c cancers are generally characterized by low mutational burden and few recurrently mutated genes.

15 h acute myeloid leukemia (AML) may depend on mutational burden and its interaction with other mutatio

16 Although ASD females showed higher mutational burden and lower cognition, the excess mutati

17 The cell cycle subtype showed highest mutational burden (ANOVA p < 0.01) and the smallest amou

18 tosis and JAK2V617F mutational status and/or mutational burden are now under active investigation.

19 This figure is comparable to the expected mutational burden associated with an additional 21 years

20 g cancer cell line, NCI-H209, to explore the mutational burden associated with tobacco smoking.

21 rate and selfish selection contribute to the mutational burden borne by the paternal germline.

22 ts detected in target cells, rather than the mutational burden carried by such DNAs, corresponded clo

23 Whole-exome sequencing shows a low mutational burden, consistent with genomics studies, but

24 (6 families, 12.5%), indicating a potential mutational burden contributing to disease expression.

25 antigens by tumor cells, rather than overall mutational burden, determines the response to checkpoint

26 cases, there were significant differences in mutational burden, driver mutations, mutational processe

27 nce to cancer immunotherapy, including tumor mutational burden (e.g., microsatellite instability), co

28 s may explain this diversity, with increased mutational burdens favoring reduced genome size and comp

29 te apoptosis and the removal of cells with a mutational burden from the population, thereby keeping t

30 tegies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex

31 encing data has illuminated the scope of the mutational burden in cancer genomes, identifying pattern

32 8 mutations per Mb, equivalent to the median mutational burden in common leukaemias.

33 The average aggregate mutational burden in elderly subjects was 2 x 10(-4) mut

34 ertant mosaicism; and provided evidence of a mutational burden in mixed PIDD immunophenotypes.

35 rare mutations and demonstrate that somatic mutational burden in normal human tissues can vary by se

36 ction plays a prominent role in reducing the mutational burden in populations.

37 y homologous recombination based on its high mutational burden in samples harbouring BRCA1 or BRCA2 m

38 ence of microsatellite instability and tumor mutational burden in SBA suggests a potential role for i

39 e pattern of polymorphisms suggests that the mutational burden in vivo is because of oxidative DNA da

40 Mutational burden increased with impaired nucleotide exc

41 opulations can be achieved when a sufficient mutational burden is applied.

42 between TADs and epigenetic marks, as tumor mutational burden is known to be coupled to chromatin st

43 d resequencing studies unbiased for previous mutational burden is necessary to delineate the complexi

44 We further show that the increased mutational burden is particularly high at genomic sites

45 tified in two malignant melanomas with a low mutational burden (number of mutation per megabase, 0.8

46 The overall mutational burden of a tumor is considered to be a predi

47 Mutational burden of both genes correlated with X-inacti

48 rovided us with a precise description of the mutational burden of cancers, making it possible to iden

49 The mutational burden of melanoma patients is an order of ma

50 gard to damage bypass, may contribute to the mutational burden of the cell.

51 primary causes of BBS that contribute to the mutational burden of the disorder.

52 sts specifically from elderly subjects, with mutational burdens of up to 50%.

53 We observe no overall increase in tumor mutational burden post-chemotherapy, though a significan

54 Compared with GCs, IMs exhibit low mutational burdens, recurrent mutations in certain tumor

55 rmine that TSC lesions contain a low somatic mutational burden relative to carcinomas, a subset featu

56 ional burden and lower cognition, the excess mutational burden remained, even after adjustment for th

57 phenotype in two cases with >8 times higher mutational burden than the remaining mean was identified

58 ce of this preservation and to determine the mutational burden that active sites can tolerate, we ran

59 deleterious alleles by 26%, and shifted the mutational burden toward common variants; (ii) deleterio

60 The decreased mutational burden was not due to rapamycin-induced cell

61 en tumor differentiation and overall somatic mutational burden, which also likely explains the highly

62 ression, we have demonstrated an increase in mutational burden with tumor progression at all length s